Excelsior Correspondent
JAMMU, Mar 14: Keeping in line with Govt move to incentivize firms to boost domestic production of Active Pharmaceutical Ingredient (APIs) and reduce dependence on imports, the CSIR-Indian Institute of Integrative Medicine, Jammu has entered into an agreement with M/s Racemix Molecules Pvt Ltd, a Jammu based Pharmaceutical Company, to do collaborative research & development and industrial production of APIs of the life saving drugs.
While giving the detail of research and development work planned to be carried out under this agreement, Dr Ram Vishwakarma, Director CSIR-IIIM Jammu, informed that for past quite sometime, 40 percent of world market of APIs was with India. However, he added, the aggressive pricing policy of the countries like China, which started selling these APIs at very cheaper rate, caused severe effect to the Indian Pharmaceutical industries involved in the production of APIs, thereby increasing their dependence on imported APIs.
Dr Ram also disclosed that this agreement signing is the follow-up action of successful developing the “know how process for fluxamime maleate” which is an antidepressant drug and now M/s Anphar is going to start the production of commercial batches in its good manufacturing practice (GMP) facility. After successful accomplishment of the lab scale synthesis of fluxamime maleate, CSIR-IIIM and M/s Racemix Molecules Pvt Ltd (a subsidiary of M/s Anphar) have signed the umbrella agreement under which they would work together for the synthesis of intermediates of API, production of commercial batches of fluxamime maleate and APIs of many other life-saving drugs.
“Witnessing the current World situation where various diseases are spread world wide and most of the countries have stopped the export of drugs, CSIR-IIIM with state of the art research facilities has taken the initiative to actively support the API industry and to develop our own APIs in our country itself. This will not only generate huge job opportunities but also develop national health security in India. This agreement will be a landmark and will work as a model to develop the API industry which can value about hundreds of billion dollar,” maintained Dr Ram.
The agreement was signed by Dr Ram Vishwakarma and Ankit Gupta, Director, M/S Racemix Molecules Pvt Ltd, here today, in the presence of other senior functionaries from both sides.
Follow our WhatsApp channel
